Comparison between hirudin and citrate in monitoring the inhibitory effects of P2Y12 receptor antagonists with different platelet function tests

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 11, 2009, Pages 1929-1932

  Pittens, C A C M ^a   Bouman, H J ^a   Van Werkum, J W ^a   Ten Berg, J M ^a   Hackeng, C M ^b  

^a Department of Cardiology ^*  (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; CANGRELOR; CITRATE TRISODIUM; CITRIC ACID; HIRUDIN; LEPIRUDIN; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; RECEPTOR BLOCKING AGENT; THROMBIN RECEPTOR ACTIVATING PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; DRUG EFFICACY; FEMALE; FUNCTION TEST; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; INTERMETHOD COMPARISON; LETTER; LIGHT TRANSMISSION AGGREGOMETRY; MALE; MONITORING; MULTIPLE ELECTRODE AGGREGOMETRY; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADULT; CITRIC ACID; CORONARY ARTERY DISEASE; DRUG MONITORING; FEMALE; HIRUDINS; HUMANS; MALE; PLATELET FUNCTION TESTS; RECEPTORS, PURINERGIC P2; YOUNG ADULT;

EID: 70449389910     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03585.x     Document Type: Letter

References (10)

1. Lordkipanidze M, Pharand C, Nguyen TA, Schampaert E, Diodati JG. Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition. Ther Drug Monit 2008, 30:372-8.
2. van Werkum JW, Heestermans AACM, Deneer VHM, Hackeng CM, ten Berg JM. Clopidogrel resistance: fact and fiction. Future Cardiol 2006, 2:215-28.
3. van Werkum JW, Hackeng CM, Smit JJ, van't Hof AW, Verheugt F, ten Berg JM. Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence. Future Cardiol 2008, 8:33-55.
4. Lyon ME, Drobot DW, Harding SR, Lyon AW. Evaluation of the thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginine chloromethylketone (PPACK) with the factor Xa inhibitor 1,5-dansyl-L-glutamyl-L-glycyl-L-arginine chloromethylketone (GGACK) as anticoagulants for critical care clinical chemistry specimens. Clin Chim Acta 1999, 280:91-9.
5. Bouman HJ, van Werkum JW, Hackeng CM, Verheugt FW, ten Berg JM. The importance of anticoagulant agents in measuring platelet aggregation in patients treated with clopidogrel and aspirin. J Thromb Haemost 2008, 6:1040-2.
6. Frelinger AL, Jakubowski JA, Li Y, Barnard MR, Fox ML, Linden MD, Sugidachi A, Winters KJ, Furman MI, Michelson AD. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: influence of other blood cells, calcium, and aspirin. Thromb Haemost 2007, 98:192-200.
7. Labarthe B, Theroux P, Angioi M, Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 2005, 46:638-45.
8. Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006, 96:781-8.
9. Johnson A, Dovlatova N, Heptinstall S. Multiple electrode aggregometry and P2Y(12) antagonists. Thromb Haemost 2008, 99:1127-9.
10. van Werkum JW, Kleibeuker M, Mieremet N, ten Berg JM, Hackeng CM. Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation?. J Thromb Haemost 2007, 5:884-6.